Key result
Intramyocardial cellular voltage amplitude measurement serves as a reliable noninvasive alternative to endomyocardial biopsy for diagnosing early acute rejection after heart transplantation.
Why the study?
Does intramyocardial cellular voltage amplitude measurement diagnose acute rejection in heart transplantation patients?
Does intramyocardial cellular voltage amplitude measurement diagnose acute rejection in heart transplantation patients?
Answers are grounded in this paper and cite their sources.
Intramyocardial cellular voltage amplitude measurement is proposed as a potential noninvasive alternative to endomyocardial biopsy for the early diagnosis of acute rejection after heart transplantation.
Acute rejection is one of the critical complications of heart transplantation. Early diagnosis and treatment of acute rejection following heart transplantation prevent the graft rejection and improve the survival rate. Currently, right ventricular endomyocardial biopsy (EMB) is considered the gold standard for the diagnosis of acute cardiac rejection. However, it is far from being comfortable method for the patients due its complicated implication technique and invasive nature. About 5-6% of the patients die within the first year of heart transplantation due to undiagnosed rejection or late diagnosis using biopsy technique. Intramyocardial cellular voltage amplitude measurement can be used as a noninvasive method for the diagnosis of and treatment of early acute rejection after heart transplantation.
No takes yet. Share an insight, caveat, or question.
Deniz Çevirme (2012) conducted a review in Acute rejection after heart transplantation. Intramyocardial electrogram (IMEG) vs. Endomyocardial biopsy (EMB) was evaluated. Intramyocardial cellular voltage amplitude measurement serves as a reliable noninvasive alternative to endomyocardial biopsy for diagnosing early acute rejection after heart transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: